The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of an educational video titled “Proteogenomics Research: On the Frontier of Precision Medicine." Launched at the HUPO2017 Global Leade...
Oral squamous cell carcinoma (OSCC) is a major oral cancer subtype that is the fourth most common cancer affecting Taiwanese men. Despite known risk behaviors such as cigarette smoking, alcohol drinking, and betel nut chewing often indulged by Taiwanese men, the genetic contribution to the incide...
The Human Proteome Organization (HUPO) and Prof Steve Pennington, UCD, chair of the organizing committee of HUPO2017 (the 16th HUPO World Congress) in collaboration with the National Cancer Institute’s (NCI) International Cancer Proteogenome Consortium (ICPC) announce that they will host a HUPO20...
The journal Molecular & Cellular Proteomics (MCP), in collaboration with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), part of the National Institutes of Health, announce new guidelines and requirements for papers describing the development a...
Pacific Northwest National Laboratory (PNNL) investigators in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), announces the public release of 98 targeted mass spectrometry-based assays for ovarian cancer research studies. Chosen based on proteogen...
The National Cancer Institute (NCI) Office of Cancer Clinical Proteomics Research (OCCPR), part of the National Institutes of Health, and the U.S. Food and Drug Administration (FDA) has signed a Memorandum of Understanding (MOU) in proteogenomic regulatory science. This will allow the agencies t...
This week, we are excited to announce the launch of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Proteogenomics Computational DREAM Challenge. The aim of this Challenge is to encourage the generation of computational methods for extracting information from...
Dr. Henry Rodriguez, director of the Office of Cancer Clinical Proteomics Research (OCCPR) at NCI, speaks with ecancer television at WIN 2017 about the translation of the proteins expressed in a patient's tumor into a map for druggable targets. By combining genomic and proteomic information (prot...
This week, the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), part of the National Institutes of Health, announced its aim to further the convergence of proteomics with genomics – “proteogenomics,” to better understand the molecular basis of cancer a...
Proteogenomics, integration of proteomics, genomics, and transcriptomics, is an emerging approach that promises to advance basic, translational and clinical research. By combining genomic and proteomic information, leading scientists are gaining new insights due to a more complete and unified un...
For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks another potential marker — rogue proteins — that may be driving cancer cells...
The Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) network, which is a partnership among the National Cancer Institute, Department of Defense, and Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research Center to create a panel...
The Obama administration's cancer moonshot has brought three Federal agencies together. Specifically, the National Cancer Institute (NCI), the Department of Defense (DoD), and the Department of Veterans Affairs (VA) have formed a new collaboration using state-of-the-art research methods in proteo...
This week, Vice President Joe Biden announced progress on his global vision for the Cancer Moonshot. Announced were 10 new Memoranda of Understanding or Memoranda of Cooperation for international cancer research and care, as well as new efforts in the emerging scientific areas of precision oncol...
University of Victoria Genome British Columbia Proteomics Centre, a leader in proteomic technology development, has partnered with the U.S. National Cancer Institute (NCI) to make targeted proteomic assays accessible to the community through NCI’s CPTAC Assay Portal (https://assays.cancer.gov)....
The White House Office of the Vice President has announced the signing of three Memoranda of Understanding (MOUs) that will make available an unprecedented international dataset to advance cancer research and care. An MOU between the National Cancer Institute (NCI) at the National Institutes of H...
July 11, 2016 — In the spirit of collaboration inspired by the Vice President’s Cancer Moonshot, the Department of Veterans Affairs (VA), the Department of Defense (DoD), and the National Cancer Institute (NCI) are proud to announce a new tri-agency coalition that will help cancer patients by ena...
June 29, 2016 — In what is believed to be the largest study of its kind, scientists at Johns Hopkins University (JHU) and Pacific Northwest National Laboratory (PNNL) led a multi-institutional collaborative project that comprehensively examined the collections of proteins in the tumors of 169 ova...
News Release: May 25, 2016 — Building on data from The Cancer Genome Atlas (TCGA) project, a multi-institutional team of scientists has completed the first large-scale “proteogenomic” study of breast cancer, linking DNA mutations to protein signaling and helping pinpoint the genes that drive canc...
The National Cancer Institute will hold a public Pre-Application webinar on Wednesday, January 13, 2016 at 12:00 p.m. (EST) for the Funding Opportunity Announcement (FOA) RFA-CA-15-022 entitled “Proteogenomic Translational Research Centers for Clinical Proteomic Tumor Analysis Consortium (U01).”...